Health-related quality of life, mental and sleep disordes of patients with pulmonary arterial hypertension participating in the Polish PH treatment program
DOI:
https://doi.org/10.12775/JEHS.2025.77.56684Keywords
Health-related quality of life (HRQoL), pulmonary arterial hypertension (PAH)Abstract
Pulmonary arterial hypertension (PAH) is a rare, chronic disease, that leads to the development of a range of heart failure-related symptoms that directly affect an individual's functioning. The aim of the study was to assess health-related quality of life (HRQoL) of the PAH patients. Participants completed several specific survey questionnaires. The mean scores obtained in each domain of the PAH-SYMPACT HRQoL questionnaire were: cardiopulmonary symptoms 1.02±0.57, cardiovascular symptoms 0.54±0.5, physical effects 1.24±0.9, mental effects 0.99±SD=0.82. The average scores on the anxiety and depression scales were 5.33±3.31, 4.4±3.78, respectively, which indicates their low severity. The mean score obtained on the Pittsburgh Sleep Quality Scale (PSQI) was 8.7±4.64 and represented the to poor sleep quality affecting the study group. Sleep disorders were present in the majority of the subjects and had the most significant impact on reducing the HRQoL in the study group. Anxiety and depressive disorders were present in a small percentage of the subjects. The results showed that the best predictor of HRQoL evaluation is sleep quality assessment.
References
Alnuaimat H, Patel S, Cope, J. Pulmonary arterial hypertension and associated conditions. DM. 2016;62:382-405. DOI: 10.1016/j.disamonth.2016.03.006
Wapner J, Matura LA. An update on pulmonary arterial hypertension. JNP. 2015;11.5:551-559. DOI: 10.1016/j.nurpra.2015.02.004.
Frumkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev. 2012;64.3:583-620. DOI: 10.1124/pr.111.005587.
Montani D, Günther S, Dorfmüller P, Perros F, Girerd B, Garcia G, Jaïs X, Savale L, et al. Orphanet J Rare Dis. 2013;8:1-28. DOI: 10.1186/1750-1172-8-97.
Ghigna MR, Dorfmüller P. Pulmonary vascular disease and pulmonary hypertension. Diagn Histopathol. 2019;25.8:304-312. DOI: 10.1016/j.mpdhp.2019.05.002.
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43.38:3618-731. Erratum in: Eur Heart J. 2023;44.15:1312. DOI: 10.1093/eurheartj/ehac237.
Cullivan S, Gaine S, Sitbon O. New trends in pulmonary hypertension. ERR. 2013;32.167. DOI: 10.1183/16000617.0211-2022
Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021;11.1:2045894020977300. DOI: 10.1177/2045894020977300
Korsholm K, Andersen A, Kirkfeldt RE, Hansen KN, Mellemkjær S, Nielsen-Kudsk JE. Survival in an incident cohort of patients with pulmonary arterial hypertension in Denmark. Pulm Circ. 2015;5.2:364-369. DOI: 10.1086/681270.
Cenedese E, Speich R, Dorschner L, Ulrich S, Maggiorini M, Jenni R, Fischler M. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J. 2006;28.4:808-815. DOI: 10.1183/09031936.06.00130405.
Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, et al. Five-year outcomes of patients enrolled in the REVEAL registry. Chest. 2015;148:1043–54. DOI: 10.1378/chest.15-0300.
Gu S, Hu H, Dong H. Systematic review of health-related quality of life in patients with pulmonary arterial hypertension. Pharmacoeconomics. 2016;34:751-770. DOI: 10.1007/s40273-016-0395-y.
Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. ERR. 2015;24.138:621-629. DOI: 10.1183/16000617.0063-2015.
Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension. Chest. 2004;126.5:1452-1459. DOI: 10.1378/chest.126.5.1452.
Chen H, Taichman DB, Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc. 2018;5.5:623-630. DOI: 10.1513/pats.200802-020SK.
Olsson KM, Meltendorf T, Fuge J, Kamp JC, Park DH, Richter MJ, et al. Prevalence of mental disorders and impact on quality of life in patients with pulmonary arterial hypertension. Fpsyt. 2021;12:667602. DOI: 10.3389/fpsyt.2021.667602.
Taichman DB, Shin J, Hud L, Archer-Chicko C, Kaplan S, Sager JS, Gallop R, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res. 2005;6:1-10. DOI: 10.1186/1465-9921-6-92.
Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E. Validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) for the Australian and New Zealand population. Respirology. 2011;16.8:1235-1240. DOI: 10.1111/j.1440-1843;2011:02030.x.
Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, Torbicki A. End point and clinical trial designs in pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:48S–55S. DOI: 10.1016/j.jacc.2004.02.010.
Reeves GEM, Shepherd J, Collins NJ, Twaddell S, Harjit Singh, R. Assessing quality of life in pulmonary arterial hypertension: An independent prognostic marker. Pulm. Circ. 2024;14.2:e12380. DOI: 10.1002/pul2.12380.
Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, et al. Psychometric validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) questionnaire: results of the SYMPHONY trial. Chest. 2018;154.4:848-861. DOI: 10.1016/j.chest.2018.04.027.
McCollister D, Shaffer S, Badesch DB, Filusch A, Hunsche E, Schüler R, et al. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res. 2016;17:1-12. DOI 10.1186/s12931-016-0388-6.
Sarzyńska K, Polański J, Kopeć G, Mroczek E, Jankowska-Polańska B. Cultural adaptation and validation of the Polish version of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) questionnaire. Pol Heart J. 2021;79.12:13721374. DOI: 10.33963/KP.a2021.0149.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70. DOI: 10.1111/j.1600-0447.1983.tb09716.x.
Crawford JR, Henry JD, Crombie C, Taylor EP. Normative data for the HADS from a large non‐clinical sample. Br J Clin Psychol. 2001;40.4:429-434. DOI: 10.1348/014466501163904.
Watrowski R, Rohde A. Validation of the Polish version of the Hospital Anxiety and Depression Scale in three populations of gynecologic patients. AMS. 2014;10.3:517-524. DOI: 10.5114/aoms.2013.36520.
Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry research. 1989;28.2:193-213. DOI: 10.1016/0165-1781(89)90047-4.
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2023. URL https://www.R-project.org/.
DuBrock HM, Reddy YN, Durst LA, Schroeder DR, Park G, Cajigas HR, et al. The feasibility and value of assessing patient‐reported outcomes in pulmonary arterial hypertension. Pulm Circ. 2022;12.4:e12143. DOI: 10.1002/pul2.12143.
McCollister DH, Beutz M, McLaughlin V, Rumsfeld J, Masoudi FA, Tripputi M, Yaeger T, Weintraub P, Badesch DB. Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics. 2010;51.4:339-339. DOI: 10.1016/S0033-3182(10)70706-4.
Yorke J, Armstrong I. The assessment of breathlessness in pulmonary arterial hypertension: reliability and validity of the Dyspnoea-12. EJCN. 2014;13.6:506-514. DOI: 10.1177/1474515113514891.
Amedro P, Basquin A, Gressin V, Clerson P, Jais X, Thambo JB, et al. Health-related quality of life of patients with pulmonary arterial hypertension associated with CHD: the multicentre cross-sectional ACHILLE study. Cardiol Young. 2016;26.7:250-9. DOI: 10.1017/S1047951116000056.
Pfeuffer E, Krannich H, Halank M, Wilkens H, Kolb P; Jany B, et al. Anxiety, Depression, and Health-Related QOL in Patients Diagnosed with PAH or CTEPH. Lung. 2017;195.6:759-768. DOI: 10.1007/s00408-017-0052-z.
Flanagan S, Damery S, Combes G. The effectiveness of integrated care interventions in improving patient quality of life (QoL) for patients with chronic conditions. An overview of the systematic review evidence. Health and quality of life outcomes. 2017;15:1-11. DOI: 10.1186/s12955-017-0765-y.
Bekelman DB, Plomondon ME; Carey, EP, Sullivan MD, Nelson KMl, Hattler B, et al. Primary Results of the Patient Centered Disease Management (PCDM) for Heart Failure Study: A Randomized Clinical Trial. JAMA Intern Med. 2015;175:725–32. DOI: 10.1001/jamainternmed.2015.0315.
Zhai Z, Zhou X, Zhang S, Xie W, Wan J, Kuang T, et al. The impact and financial burden of pulmonary arterial hypertension on patients and caregivers: results from a national survey. Medicine. 2017;96.39.
Matura LA, McDonough A, Hanlon AL, Carroll DL, Riegel B. Sleep disturbance, symptoms, psychological distress, and health-related quality of life in pulmonary arterial hypertension. EJCN. 2015;14.5:423-430. DOI: 10.1177/1474515114537951.
Batal O, Khatib OF, Bair N, Aboussouan LS, Minai OA. Sleep quality, depression, and quality of life in patients with pulmonary hypertension. Lung;2011;189:141-149. DOI: 10.1007/s00408-010-9277-9.
Budhiraja R, Siddiqi TA, Quan SF. Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management. JCSM. 2015;11.3:59-270. DOI: 10.5664/jcsm.4540.
Chao HY, Yee BJ, Hsu CH, Chen HM, Lau, EM. Sleep-related disorders in patients with precapillary pulmonary hypertension. Sleep Med. Rev. 2024;101972. DOI: 10.1016/j.smrv.2024.101972.
Ulrich S, Fischler M, Speich R, Bloch KE. Sleep-related breathing disorders in patients with pulmonary hypertension. Chest. 2008;133.6:1375-1380. DOI: 10.1378/chest.07-3035.
Rafanan AL, Golish JA, Dinner DS., Hague LK, Arroliga AC. Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest. 2001;120.3:894-899. DOI: 10.1378/chest.120.3.894.
Minic M, Granton JT, Ryan CM. Sleep disordered breathing in group 1 pulmonary arterial hypertension. JCSM. 2014;10.3:277-283. DOI: 10.5664/jcsm.3528.
Schulz R, Baseler G, Ghofrani HA, Grimminger F, Olschewski H, Seeger, W. Nocturnal periodic breathing in primary pulmonary hypertension. Eur Respir J. 2002;19.4:658-663. DOI: 10.1183/09031936.02.00225102.
Shaarawy H; Elhawary A. Study of sleep related respiratory disorders in patients with idiopathic pulmonary arterial hypertension. Egypt J Chest Dis Tuberc. 2016;65:233-237. DOI: 10.1016/j.ejcdt.2015.12.011.
Benjamin N, Echampati I, Harutyunova S, Eichstaedt CA, Egenlauf B.; Ulrich, S.; Grünig, E.; Xanthouli, P. Long-term oxygen therapy in precapillary pulmonary hypertension–SOPHA study. Scientific Reports. 2024, 14.1, 22038. DOI: 10.1038/s41598-024-70650-w.
Zuurbier, L.A.; Luik, A.I.; Leening, M.J.; Hofman, A.; Freak-Poli, R.; Franco, O.H.; Stricker, B.H.; Tiemeier, H. Associations of heart failure with sleep quality: the Rotterdam Study. JCSM. 2015, 11.2, pp. 117-121. DOI: 10.5664/jcsm.4454.
Nunes, D.M.; Mota, R.M.S.; de Pontes Neto, O.L.; Pereira, E.D.B.; de Bruin, V.M.S.; de Bruin, P.F.C. Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung. 2009, 187, pp. 159-163. DOI: 10.1007/s00408-009-9147-5.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Kathie Sarzyńska, Beata Jankowska-Polańska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 73
Number of citations: 0
